(Q37800101)

English

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

scientific article published on October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 August 2017

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies (English)

1 reference

Europe PubMed Central

23 August 2017

0 references

cerebrospinal fluid

0 references

1 reference

based on heuristic

inferred from title

Claudia Trenkwalder

4

object named as

Claudia Trenkwalder

1 reference

Europe PubMed Central

23 August 2017

Michael G Schlossmacher

object named as

Michael G Schlossmacher

5

0 references

Brit Mollenhauer

1

object named as

Brit Mollenhauer

1 reference

Europe PubMed Central

23 August 2017

author name string

Omar M A El-Agnaf

2

1 reference

Europe PubMed Central

23 August 2017

Katrin Marcus

3

1 reference

Europe PubMed Central

23 August 2017

publication date

1 October 2010

1 reference

Europe PubMed Central

23 August 2017

Biomarkers in Medicine

1 reference

Europe PubMed Central

23 August 2017

4

1 reference

Europe PubMed Central

23 August 2017

5

1 reference

Europe PubMed Central

23 August 2017

683-699

1 reference

Europe PubMed Central

23 August 2017

Novel Risk Markers and Clinical Practice

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Amyloid beta-peptide is produced by cultured cells during normal metabolism

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Choroid plexus: biology and pathology

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Safety and acceptability of the research lumbar puncture.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Dynamics of brain-derived proteins in cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Biomarker method validation in anticancer drug development

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Multiple system atrophy: a primary oligodendrogliopathy.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Lewy body-related alpha-synucleinopathy in the aged human brain.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Multiple-system atrophy: a new alpha-synuclein disease?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

alpha-Synuclein locus triplication causes Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Genetics of Parkinson disease: paradigm shifts and future prospects.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The biochemistry of Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Yeast cells provide insight into alpha-synuclein biology and pathobiology

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Intravesicular localization and exocytosis of alpha-synuclein and its aggregates.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Determination of alpha-synuclein concentration in human plasma using ELISA.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Clinical proteomics in neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Red blood cells are the major source of alpha-synuclein in blood.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Identification of novel APP/Abeta isoforms in human cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Biomarkers in Parkinson's disease: a funder's perspective

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

The choroid plexus removes beta-amyloid from brain cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.90

21 January 2018

Identifiers

10.2217/BMM.10.90

1 reference

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37800101&oldid=2157200263"